Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention
Theriva Biologics, Inc. shares surged Thursday after news that data from a Phase 1 trial of its main cancer drug VCN-01 appeared in Clinical Cancer Research. Traders jumped on TOVX, which last traded at $0.4252, up 74.6%. Volume was 144.7 million shares. Theriva’s market cap is still under $20 million, at about $17.0 million. Headline risk moved for Theriva this morning, but it wasn’t a drug approval. The company said at 8:00 a.m. ET it got online-first publication in Clinical Cancer Research of results for its VCN-01 trial in head and neck squamous cell carcinoma, or HNSCC. HNSCC covers cancers starting in the lining of the mouth, throat or head-and-neck tissue.